![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » GW Pharmaceuticals’ Epidiolex Shines in Phase 3
GW Pharmaceuticals’ Epidiolex Shines in Phase 3
March 18, 2016
GW Pharmaceuticals saw positive results in a Phase 3 study evaluating its epilepsy candidate Epidiolex for the treatment of Dravet syndrome.
Patients treated with Epidiolex experienced a “significant reduction” in seizure frequency versus the placebo.
GW has two ongoing Phase 3 trials evaluating Epidiolex in Lennox-Gastaut syndrome and second Phase 3 trial in Dravet syndrome.
Additionally, Epidiolex garnered fast track status from the FDA and orphan drug designation from the European Commission for Dravet syndrome.
Upcoming Events
-
21Oct